More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

restricting the bulk compounding of GLP-1 formulations under the 503A exemption. Citi warns that a similar decision regarding Semaglutide, expected within the next 12 months, could further ...

With Tirzepatide now officially the FDA’s shortage list, it is more likely than not that Semaglutide is removed ... as it would only be able to compound GLP-1s by changing the formulation ...

U.S. laws allow compounding pharmacies and facilities to produce compounded versions of FDA-approved drugs during shortages of the branded version. A tight supply of Novo's semaglutide and Lilly's ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...